Related Experiment Videos
Propylthiouracil for alcoholic liver disease.
1Ospedale San Paolo, Divisione di Medicina Generale, Via Terracina, Napoli, Campania, Italy 80100. arambaldi@hotmail.com
The Cochrane Database of Systematic Reviews
|October 20, 2005
Summary
Propylthiouracil offers no significant benefit for alcoholic liver disease patients. This drug did not improve mortality or liver health and was linked to adverse events, showing no evidence for its use.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Internal Medicine
Background:
- Randomized clinical trials have investigated propylthiouracil for alcoholic liver disease.
- The efficacy and safety of propylthiouracil in this patient population remain a key clinical question.
Purpose of the Study:
- To systematically assess the benefits and harms of propylthiouracil in patients diagnosed with alcoholic liver disease.
- Evaluate the impact of propylthiouracil on mortality, liver complications, and histological outcomes.
Main Methods:
- A comprehensive search of multiple electronic databases (Cochrane Hepato-Biliary Group, Cochrane Central, MEDLINE, EMBASE, Web of Science) up to May 2005.
- Inclusion of six randomized clinical trials involving 710 patients with various stages of alcoholic liver disease (steatosis, fibrosis, hepatitis, cirrhosis).
- Analyses followed the intention-to-treat principle, with methodological quality assessment of included trials.
Main Results:
- Propylthiouracil showed no statistically significant effect on all-cause mortality (RR 0.93, 95% CI 0.66-1.30) or liver-related mortality (RR 0.80, 95% CI 0.50-1.29).
- No significant improvements were observed in liver disease complications or liver histology.
- A non-significant increase in non-serious adverse events and rare serious events like leukopenia were associated with propylthiouracil use.
Conclusions:
- Current evidence does not support the use of propylthiouracil for treating alcoholic liver disease.
- The drug demonstrated no significant benefits regarding mortality, disease progression, or liver histology.
- Propylthiouracil is associated with adverse events, and wide confidence intervals preclude definitive conclusions, thus advising against its use outside clinical trials.